| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Plasma kallikrein |
|---|
| Ligand | BDBM455230 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | Inhibitory Activity of Exemplary Compounds against Plasma Kallikrein |
|---|
| EC50 | <1.0±n/a nM |
|---|
| Citation |  Papaioannou, N; Fink, SJ; Miller, TA; Shipps, Jr., GW; Travins, JM; Ehmann, DE; Rae, A; Ellard, JM Inhibitors of plasma kallikrein and uses thereof US Patent US10730874 Publication Date 8/4/2020 |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Plasma kallikrein |
|---|
| Name: | Plasma kallikrein |
|---|
| Synonyms: | Fletcher factor | KLK3 | KLKB1 | KLKB1_HUMAN | Kallikrein | Kininogenin | Plasma kallikrein heavy chain | Plasma kallikrein light chain | Plasma prekallikrein |
|---|
| Type: | Protein |
|---|
| Mol. Mass.: | 71391.16 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P03952 |
|---|
| Residue: | 638 |
|---|
| Sequence: | MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLF
SFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVD
MRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIK
VLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFF
TFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGV
DFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRI
AYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCG
GSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEG
NHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNI
PLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGE
GCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA
|
|
|
|---|
| BDBM455230 |
|---|
| n/a |
|---|
| Name | BDBM455230 |
|---|
| Synonyms: | US10730874, Compound I-242 | US11352356, Compound I-242 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C27H23ClFN11O3 |
|---|
| Mol. Mass. | 603.995 |
|---|
| SMILES | CCn1ncn(-c2cc(cn3cc(Cn4cc(nn4)C(=O)NCc4ncn5ccc(Cl)c(F)c45)nc23)C2CC2)c(=O)c1=O |
|---|
| Structure | 
|
|---|
Search and Browse
